Hemostemix Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas A. Smeenk
- Full Time Employees
- 488
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 707-7th Avenue SW Calgary AB Canada T2P 3H6
- IPO Date
- Jan 7, 2016
- Website
- hemostemix.com
- Similar Companies
- Business
- Hemostemix Inc. is a clinical-stage biotechnology company specializing in the development, manufacture, and commercialization of blood-derived stem cell therapies for the treatment of medical conditions inadequately addressed by current therapeutics. The company's core products include ACP-01, an autologous angiogenic cell precursor therapy primarily targeted at cardiovascular diseases such as angina, ischemic and dilated cardiomyopathy, peripheral arterial disease, chronic limb threatening ischemia, and congestive heart failure. Hemostemix also develops NCP-01, a preclinical neural cellular precursor therapy aimed at neuropathic pain and motor function recovery. The company operates primarily in Canada with activities extending through clinical trials and compassionate treatments supported by regulatory frameworks in North America. Founded in 2010 and headquartered in Calgary, Alberta, Hemostemix leverages proprietary patented stem cell technology and has secured a global royalty-free license for CytoImmune’s BioReactor stem cell manufacturing technologies. The company has advanced its Automated Cell Therapy System (ACTS), a robotics-based platform designed to scale ACP-01 production significantly, with an annual capacity potential exceeding 23,000 therapies, each priced around $50,000. Recent major developments include a series of private placements raising multi-million-dollar capital to support commercialization, operational expansion, and debt settlement. Hemostemix has initiated acquisitions of cardiology medical practices in the Dominican Republic to create a sustainable patient flow for ACP-01 treatments and enhance practitioner engagement, supporting business growth through a strategic roll-up of profitable medical practices. The company is also progressing clinical studies for new therapeutic indications, including a recently filed ethics approval for a vascular dementia study and expanding indications for refractory angina treatment. This strategy underpins Hemostemix's objective to commercialize its stem cell therapies broadly with a focus on generating predictable patient treatment volume and cash flow through integrated clinical operations and innovative manufacturing scalability. Hemostemix is publicly traded under TSXV: HEM, OTCQB: HMTXF, and FSE: 2VF0.
Company News
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
Hemostemix Non Brokered Private Placement
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Hemostemix Grants Stock Options
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Hemostemix Closes $360,000 First Tranche of Private Placement
Hemostemix' $1,000,000 Private Placement and Update
Hemostemix Leadership Attending Abundance360 Summit
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Hemostemix Grants Stock Options
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations